Nab-paclitaxel Efficacy in the Orthotopic Model of Human Breast Cancer Is Significantly Enhanced By Concurrent Anti–Vascular Endothelial Growth Factor A Therapy

Heterogeneity in the angiogenic response

Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: Assessment by voxel analysis of dynamic contrast-enhanced MRI

✍ Ka-Loh Li; Lisa J. Wilmes; Roland G. Henry; Maria G. Pallavicini; John W. Park; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 783 KB

## Abstract ## Purpose To investigate the heterogeneity in the angiogenic response of a human breast cancer xenograft to a novel vascular endothelial growth factor (VEGF)‐receptor tyrosine kinase inhibitor, AG‐013736, using dynamic contrast‐enhanced MR imaging (DCE‐MRI). ## Materials and Methods